Literature DB >> 33641861

Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Douglas Tremblay1, Abdulraheem Yacoub2, Ronald Hoffman3.   

Abstract

Myeloproliferative disorders are a group of diseases morphologically linked by terminal myeloid cell expansion that frequently evolve from one clinical phenotype to another and eventually progress to acute myeloid leukemia. Diagnostic criteria for the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have been established by the World Health Organization and they are recognized as blood cancers. MPNs have a complex and incompletely understood pathogenesis that includes systemic inflammation, clonal hematopoiesis, and constitutive activation of the JAK-STAT pathway. Complications, such as thrombosis and progression to overt forms of myelofibrosis and acute leukemia, contribute significantly to morbidity and mortality of patients with MPN.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic criteria; Essential thrombocythemia; History; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera

Mesh:

Year:  2021        PMID: 33641861      PMCID: PMC8669599          DOI: 10.1016/j.hoc.2020.12.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  104 in total

1.  Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts.

Authors:  A Kimura; O Katoh; H Hyodo; A Kuramoto
Journal:  Br J Haematol       Date:  1989-08       Impact factor: 6.998

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Authors:  Martin H Cohen; Grant Williams; John R Johnson; John Duan; Jogarao Gobburu; Atiqur Rahman; Kimberly Benson; John Leighton; Sung K Kim; Rebecca Wood; Mark Rothmann; Gang Chen; Khin Maung U; Ann M Staten; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

4.  Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry.

Authors:  Melanie J Percy; Mary Frances McMullin; Simon N Jowitt; Michael Potter; Marilyn Treacy; William H Watson; Terence R J Lappin
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Spurious polycythemia.

Authors:  N J Weinreb; C F Shih
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

7.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

8.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

Review 9.  Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

Authors:  Hans Carl Hasselbalch
Journal:  Leuk Res       Date:  2012-11-20       Impact factor: 3.156

10.  Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.

Authors:  Yoshinori Ozono; Kotaro Shide; Takuro Kameda; Ayako Kamiunten; Yuki Tahira; Masaaki Sekine; Keiichi Akizuki; Kenichi Nakamura; Hisayoshi Iwakiri; Mitsue Sueta; Tomonori Hidaka; Yoko Kubuki; Shojiro Yamamoto; Satoru Hasuike; Akira Sawaguchi; Kenji Nagata; Kazuya Shimoda
Journal:  Leukemia       Date:  2020-05-29       Impact factor: 11.528

View more
  3 in total

Review 1.  Novel treatments for myelofibrosis: beyond JAK inhibitors.

Authors:  Douglas Tremblay; Ruben Mesa
Journal:  Int J Hematol       Date:  2022-02-19       Impact factor: 2.490

Review 2.  JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Authors:  Dania G Torres; Jhemerson Paes; Allyson G da Costa; Adriana Malheiro; George V Silva; Lucivana P de Souza Mourão; Andréa M Tarragô
Journal:  Biomolecules       Date:  2022-02-11

3.  Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.

Authors:  Marco Santoro; Vincenzo Accurso; Salvatrice Mancuso; Mariasanta Napolitano; Marta Mattana; Giorgia Vajana; Federica Russello; Sergio Siragusa
Journal:  Hematol Rep       Date:  2022-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.